| P50 | author | Fabienne Thomas | Q59360262 |
| | Francois Ghiringhelli | Q59388255 |
| | Marie-Anne Loriot | Q40442723 |
| | Céline Narjoz | Q58377395 |
| P2093 | author name string | Cécile Ged | |
| | Franck Broly | |
| | Marie-Christine Etienne-Grimaldi | |
| | Nicolas Picard | |
| | Marie-Pierre Gaub | |
| | Delphine Poncet | |
| | Marie-Claude Gagnieu | |
| | Régis Bouquié | |
| | Chantal Le Guellec | |
| | Jean-Christophe Boyer | |
| | Valérie Le Morvan | |
| | Sylvie Quaranta | |
| | Laurent Philibert | |
| | Collective work by Groupe de Pharmacologie Clinique Oncologique (GPCO-Unicancer) | |
| | French Réseau National de Pharmacogénétique Hospitalière (RNPGx) | |
| P2860 | cites work | PharmGKB summary: very important pharmacogene information for UGT1A1 | Q24562836 |
| | Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? | Q24670527 |
| | Function, genetic polymorphism, and transcriptional regulation of human UDP-glucuronosyltransferase (UGT) 1A1 | Q27004072 |
| | UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy | Q27851574 |
| | Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy | Q27863360 |
| | Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan | Q28249001 |
| | Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II | Q28258225 |
| | Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. | Q33783293 |
| | Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. | Q33990876 |
| | The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome | Q34057969 |
| | Pharmacogenetics: from bench to byte--an update of guidelines | Q34171192 |
| | Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature | Q34294365 |
| | UGT1A polymorphisms in a Swedish cohort and a human diversity panel, and the relation to bilirubin plasma levels in males and females. | Q34557363 |
| | Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer | Q34565071 |
| | Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. | Q34975510 |
| | A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer | Q35108413 |
| | Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer | Q35949510 |
| | Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors | Q36036684 |
| | Pharmacogenetics of irinotecan metabolism and transport: an update | Q36306816 |
| | UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. | Q36785973 |
| | Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study | Q36862851 |
| | Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer | Q36915163 |
| | UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer | Q37402459 |
| | Comprehensive variant screening of the UGT gene family | Q37418838 |
| | Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial | Q37632102 |
| | Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians | Q37712297 |
| | The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens | Q38005612 |
| | Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis | Q38016943 |
| | Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials | Q38195958 |
| | The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis | Q38202816 |
| | CPT-11 (Irinotecan) in the treatment of colorectal cancer | Q40423824 |
| | UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma | Q40426198 |
| | The current status of irinotecan (CPT-11) in the United States | Q41308032 |
| | Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups | Q42528413 |
| | Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk | Q43012426 |
| | Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. | Q43102323 |
| | Gilbert-Meulengracht's syndrome and pharmacogenetics: is jaundice just the tip of the iceberg? | Q43195722 |
| | Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism | Q43211622 |
| | Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial | Q43254499 |
| | Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia | Q43924893 |
| | UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity | Q43979778 |
| | Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). | Q44104279 |
| | Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer | Q44333734 |
| | Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study. | Q44390387 |
| | Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients | Q45009159 |
| | Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy | Q46399690 |
| | Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations | Q46411292 |
| | Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. | Q46605316 |
| | Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer | Q46789938 |
| | Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study | Q46958946 |
| | Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism | Q46980000 |
| | Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. | Q53541080 |
| | A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. | Q54320201 |
| | UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan | Q58408313 |
| P433 | issue | 3 | |
| P921 | main subject | irinotecan | Q412197 |
| P304 | page(s) | 219-237 | |
| P577 | publication date | 2015-05-04 | |
| P1433 | published in | Fundamental and Clinical Pharmacology | Q15760364 |
| P1476 | title | UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice | |
| P478 | volume | 29 | |